Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-06-23T02:19:01.649Z Has data issue: false hasContentIssue false
  • English
  • Français

One-Year Open-Label Safety and Efficacy Study of Paliperidone Extended-Release Tablets in Patients With Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Michelle Kramer ,
George Simpson ,
Valentinas Maciulis ,
Stuart Kushner ,
Yanning Liu ,
Pilar Lim ,
David Hough ,
Joseph Palumbo  and
Mariëlle Eerdekens
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: This 52-week open-label extension (OLE) to a double-blind placebo-controlled recurrence prevention study examined the long-term safety and efficacy of flexibly-dosed paliperidone extended-release (ER) tablets in patients with schizophrenia.

Methods: Patients entering the OLE either entered from the double-blind phase (placebo or paliperidone ER treatment) or entered directly from the run-in or stabilization phase (paliperidone ER) of the earlier study. During the OLE, patients were treated with flexibly-dosed paliperidone ER (3–15 mg/day; 9 mg starting dose). Safety and tolerability assessments included incidence of adverse events and extrapyramidal symptoms. Efficacy was also assessed.

Results: The study population (n=235) was predominantly men (66%), 18–58 years of age. Twelve patients (5%) experienced an adverse event requiring treatment discontinuation. One or more serious treatment-emergent adverse events were reported in 13 patients (6%). There was one death. The mean Positive and Negative Syndrome Scale total score decreased from open-label baseline to endpoint for all groups, regardless of previous double-blind treatment (placebo or paliperidone ER).

Conclusion: This year-long OLE provides information on the long-term safety and tolerability of paliperidone ER in patients with schizophrenia. The resulting safety and tolerability profile was similar to that seen in earlier short-term studies.

Type
Original Research
Information
CNS Spectrums , Volume 15 , Issue 8 , August 2010 , pp. 506 - 514
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Mancevski, B, Keilp, J, Kurzon, M, et al. Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology. 2007; 40(2): 83–92.CrossRefGoogle ScholarPubMed
2.Valenstein, M, Ganoczy, D, McCarthy, JF, Myra Kim, H, Lee, TA, Blow, FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67(10): 1542–1550.CrossRefGoogle ScholarPubMed
3.Liu-Seifert, H, Adams, DH, Kinon, BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005; 3: 21.CrossRefGoogle ScholarPubMed
4.Yamada, K, Watanabe, K, Nemoto, N, et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res. 2006; 141(1): 61–69.Google Scholar
5.Cooper, C, Bebbington, P, King, M, et al. Why people do not take their psychotropic drugs as prescribed: results of the 2000 National Psychiatric Morbidity Survey. Acta Psychiatr Scand. 2007; 116(1): 47–53.Google Scholar
6.Karlsson, P, Dencker, E, Nyberg, S, et al. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res. 2006; 81(Suppl 1): 85–86.Google Scholar
7.Kane, J, Canas, F, Kramer, M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007; 90(1–3): 147–161.Google Scholar
8.Davidson, M, Emsley, R, Kramer, M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007; 93(1–3): 117–130.Google Scholar
9.Kramer, M, Simpson, G, Maciulis, V, et al. Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007; 27(1): 6–14.Google Scholar
10.Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.Google Scholar
11.Marder, SR, Davis, JM, Chouinard, G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997; 58(12): 538–546.Google Scholar
12.Kane, JM, Lauriello, J, Laska, E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S29–S35.Google Scholar
13.Kane, JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999; 46(10): 1396–1408.CrossRefGoogle ScholarPubMed